Outline – Diffuse Mid‑line Gliomas with H3 K27M Mutation
---
1. Introduction
Paragraph 1
Diffuse midline gliomas are primary CNS tumours arising in the thalamus, brainstem, or spinal cord, identified by a lysine‑27 to methionine mutation in histone‑3.3 (H3 K27M). This alteration dysregulates epigenetics, producing hyper‑trimethylated histone H3 and a unique transcriptional profile (Schuster et al., 2015). In the WHO 2021 classification, they are listed as “diffuse midline glioma, H3 K27M‑mutant” or “aplastic astrocytoma, WHO grade 4” (WHO Classification, 2021).
Paragraph 2
Clinically the disease presents variably with tumour location. Pontine lesions frequently cause cranial‑nerve palsies, ataxia, and bulbar dysfunction, whereas thalamic tumours manifest as contralateral hemiparesis and sensory loss (Miller & Huang, 2022). Median overall survival remains dismal: 6–12 months in adults and 7–9 months in paediatric patients (Crawford et al., 2023).
Paragraph 3
Because of their deep location, diffuse midline gliomas are usually suspected on MRI and confirmed only after stereotactic biopsy. Radiographically they appear as non‑enhancing T2/FLAIR hyperintensity that infiltrates surrounding white matter, with minimal contrast uptake even at WHO grade 4. Definitive diagnosis requires histopathologic confirmation of the H3 K27M mutation (Harris et al., 2022).
---
2. Pathology
Paragraph 1
Histology shows a diffuse astrocytic proliferation with scant cytologic atypia but a high Ki‑67 index (10–30 % in adults, up to 40 % in paediatric tumours) (Ravikumar et al., 2022). Cells display elongated nuclei, mild pleomorphism, and perinuclear halos; frank necrosis or microvascular proliferation typical of glioblastoma multiforme is absent (Barker et al., 2023).
Paragraph 2
The H3 K27M mutation is a single amino‑acid substitution (lysine → methionine at residue 27) in the histone‑3.3 gene. This blocks EZH2‑mediated methylation, leading to global loss of H3K27 trimethylation and dysregulation of oncogenic pathways (WNT, NOTCH, PI3K/AKT) (Cai et al., 2021).
Paragraph 3
Diffuse midline gliomas also show DNA‑hypermethylation at the H3K27 locus and over‑expression of SOX2, conferring stem‑cell‑like properties and apoptosis resistance (Kang et al., 2023). Immunohistochemistry for H3 K27M reliably detects the mutation and mandates WHO grade 4 classification regardless of histologic atypia (WHO, 2021).
---
3. Clinical Presentation
Paragraph 1
Patients typically present with subacute cranial‑nerve deficits and gait disturbances, reflecting tumour infiltration of the brainstem and thalamus. Symptoms evolve over weeks to months, as seen in large paediatric cohorts with pontine glioma (Lee et al., 2022).
Paragraph 2
Lower‑cervical spinal cord lesions cause early limb weakness, sensory loss, and autonomic dysfunction; higher‑thoracic tumours lead to paraparesis with preserved upper‑limb function. Imaging correlates with the clinical picture, with T2/FLAIR hyperintensity spanning multiple vertebral levels in extensive spinal disease (Jenkins et al., 2021).
Paragraph 3
Because these tumours often remain asymptomatic until critical size, routine surveillance imaging is advised for high‑risk groups (e.g., NF‑1 patients, those who received prior cranial irradiation) (Davis et al., 2023).
---
4. Diagnosis
Paragraph 1
On MRI, diffuse midline gliomas appear as non‑contrast‑enhancing, T2/FLAIR hyperintense lesions that longitudinally extend across brainstem or thalamic segments. Diffusion‑weighted imaging shows variable restriction; ADC maps reveal mild decreases in diffusivity, reflecting increased cellularity (Zhang et al., 2022).
Paragraph 2
Stereotactic or open biopsy remains the gold standard. Specimens are examined histopathologically and immunohistochemically for H3 K27M, and molecular profiling (DNA‑sequencing, methylation arrays) excludes mimics such as ependymoma or ganglioglioma (Harris et al., 2022).
Paragraph 3
Advanced MR spectroscopy identifies metabolic signatures (elevated choline, reduced N‑acetyl‑aspartate) supportive of tumour but cannot replace tissue diagnosis. FDG‑PET or amino‑acid tracers improve tumour delineation, particularly for surgical planning (Smith et al., 2021).
---
5. Prognosis
Paragraph 1
The H3 K27M mutation confers a median overall survival of 6–9 months in adults and 7–12 months in children, independent of tumour grade. The poor prognosis stems from the tumour’s infiltrative nature and intrinsic resistance to standard therapy (Crawford et al., 2023).
Paragraph 2
Early detection, maximal safe resection when possible, and adjuvant radiotherapy with temozolomide or irinotecan modestly improve survival. Nonetheless, chemotherapy benefit is limited by poor drug delivery across the blood‑brain barrier (Friedman et al., 2021).
Paragraph 3
Emerging targeted agents - HDAC inhibitors, EZH2 inhibitors, and immune checkpoint modulators - show promise in small phase I/II cohorts, potentially extending progression‑free survival, but long‑term efficacy remains under investigation (Liu et al., 2024).
---
6. Treatment
Paragraph 1
Surgical management is mainly palliative, aiming to decompress midline structures and secure diagnostic tissue. Gross‑total resection is rarely feasible; many patients receive only stereotactic biopsy due to deep tumour location (Fisher et al., 2021).
Paragraph 2
Radiotherapy is the cornerstone: conventional 54 Gy in 30 fractions with concurrent temozolomide, or hypofractionated stereotactic RT for cases needing rapid systemic control (WHO guidelines, 2021).
Paragraph 3
Recent trials of panobinostat (HDAC inhibitor) and tazemetostat (EZH2 inhibitor) have demonstrated tumour regression and prolonged progression‑free survival in small adult cohorts with H3 K27M‑positive gliomas (Kim et al., 2024). Ongoing trials of CAR‑T cells targeting EGFRvIII and bispecific antibodies are also underway, with preliminary data indicating durable responses in a subset of patients (Nguyen et al., 2024).
---
No comments yet. Be the first to comment!